Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
401 genO-hCCR8/hCCL1/hFcγR preclinical mouse model for efficacy assessment of CCR8-targeting agents
- 1geOway, Lyon, Rhône-Alpes, France
- 21genOway, Lyon, France
- 32genOway, Rhone Alpes, France
Related
- 882 BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors
- Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
- 618 A novel preclinical mouse model to investigate IL-18-targeting therapies
- Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study
- 76 Tumor targeting and biodistribution of MK-4464, a CEACAM5-targeted NK cell engager, using [89Zr]MK-4464 PET in preclinical models and cancer patients
BibTeX
@article{martin2026genohccr8hccl1hfcγr,
title = {{401 genO-hCCR8/hCCL1/hFcγR preclinical mouse model for efficacy assessment of CCR8-targeting agents}},
author = {Gaëlle Martin and Fabiane Sônego and Yacine Cherifi and Patricia Isnard-Petit and Kader Thiam and Angela Pappalardo},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0401},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0401},
note = {CC BY},
}
RIS
TY - JOUR
TI - 401 genO-hCCR8/hCCL1/hFcγR preclinical mouse model for efficacy assessment of CCR8-targeting agents
AU - Gaëlle Martin
AU - Fabiane Sônego
AU - Yacine Cherifi
AU - Patricia Isnard-Petit
AU - Kader Thiam
AU - Angela Pappalardo
PY - 2026
DA - 2026/11/04
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0401
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0401
SN - 2051-1426
ER -